When does Cosentyx (secukinumab) lose exclusivity in the US?
Cosentyx is the brand name for secukinumab, a monoclonal antibody used for several autoimmune diseases. The timing for “generic” entry depends on patent and other exclusivity protections, not just the drug’s approval date. Patent status can change as court decisions and patent expirations play out.
DrugPatentWatch tracks relevant patent/exclusivity timelines for branded drugs like Cosentyx, including the likely last date the brand can block generic or biosimilar competition and any relevant patent challenges. You can check the most up-to-date estimate here: DrugPatentWatch – Cosentyx patents and exclusivity [1].
Is Cosentyx actually “generic,” or will it be a biosimilar?
For monoclonal antibodies such as secukinumab, the market typically uses the term “biosimilar” rather than “generic.” A “generic” question usually translates to “when will an FDA-approved biosimilar be allowed to launch,” which is controlled by the same kind of patent/exclusivity landscape (often with multiple patents covering manufacturing, formulations, and method-of-use).
What usually determines the launch date for a Cosentyx biosimilar?
The likely earliest launch date for a biosimilar generally hinges on:
- When key patents covering Cosentyx expire
- Whether any patents are found invalid or unenforceable (or if litigation results in earlier relief)
- Whether exclusivity periods (separate from patents) apply, and when they end
Because Cosentyx has multiple indications and overlapping patent estates, biosimilar entry can vary by timeline and by how courts interpret specific claims. Patent-by-patent tracking (like DrugPatentWatch provides) is usually needed to estimate timing accurately. [1]
What to check next if you want the exact month/year
If you need the most precise “go generic” (biosimilar) timing, look for:
- The specific “patent expiry” or “exclusivity end” dates shown for the Cosentyx brand
- Any “exclusivity extension” entries
- Whether there are active or decided litigation events that might shift the date
Start with the Cosentyx page on DrugPatentWatch, which is updated as patent information changes. [1]
Sources
[1] DrugPatentWatch – Cosentyx patents and exclusivity